Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6125807 | 1.00 | KDR (0.57) | KDRDYRK2LCKCDK6TBK1 | |
| SCHEMBL6125764 | 0.91 | KDR (0.49) | KDRLCKTBK1ITK | |
| SCHEMBL29470296 | 0.91 | KDR (0.49) | KDRLCKTBK1ITK | |
| SCHEMBL8739539 | 0.91 | KDR (0.47) | KDRDYRK2LCKTBK1ITK | |
| SCHEMBL8739692 | 0.90 | KDR (0.49) | KDRLCKTBK1ITK | |
| SCHEMBL8738726 | 0.90 | KDR (0.49) | KDRLCKTBK1ITK | |
| SCHEMBL8739138 | 0.89 | LCK (0.55) | KDRLCKTBK1CHEK1ITK | |
| SCHEMBL15673350 | 0.87 | KDR (0.57) | KDRDYRK2LCKCDK6TBK1 | |
| SCHEMBL29470485 | 0.87 | KDR (0.57) | KDRDYRK2LCKCDK6TBK1 | |
| SCHEMBL8738793 | 0.87 | CHEK1 (0.57) | KDRDYRK2CDK6CHEK1ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | KDR 4125/4885DYRK2 2424/4885LCK 212/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885DYRK2 2424/4885LCK 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.